EC Number   |
Application |
Reference |
|---|
   3.4.21.35 | biotechnology |
the chicken oviduct-specific transient expression system can produce relatively high level of authentic recombinant enzyme with a potential for further development for therapeutic use |
670649 |
| 3.4.21.35 | drug development |
pre-treatment with tissue kallikrein inhibitors and/or anti-angiogenic therapies may prove to benefit future cervical cancer patients |
710169 |
| 3.4.21.35 | drug development |
recombinant adeno-associated virus-mediated tissue kallikrein gene delivery has multiple therapeutic possibilities for treating hypertension, not only by decreasing blood pressure, but also by directly inhibiting end-organ damage |
707005 |
| 3.4.21.35 | drug development |
tissue kallikrein represents a promising therapeutic strategy for ischemic stroke |
708436, 709621 |
| 3.4.21.35 | medicine |
diagnostic marker for ovarian cancer |
647540 |
| 3.4.21.35 | medicine |
enzyme complexed with prostate protease inhibitor-6 may be a naturally occuring marker of tissue damage and necrosis associated with neoplasia |
647536 |
| 3.4.21.35 | medicine |
enzyme is a diagnostic marker for prostate cancer |
647536, 647540 |
| 3.4.21.35 | medicine |
expression of tissue kallikrein exerts antihypertrophic and antifibrotic actions in the heart |
698297 |
| 3.4.21.35 | medicine |
For men with localized prostate cancer and moderate elevation of prostate-specific antigen in serum, addition of free prostate-specific antigen and enzyme data increase predictive accuracy |
668980 |
| 3.4.21.35 | medicine |
high KLK1 levels are an independent predictor for coronary artery disease |
731671 |
